Investing

Today's Market Winners and Losers

The stock market is down Monday, with the Dow Jones Industrial Average down 0.08%, the Nasdaq down 0.27% and the S&P 500 down 0.21%. Today’s winners were both getting bought out. One of today’s losers is a pharmaceutical company which reported mixed results on a drug trial, while another loser had its shares downgraded by a big bank.

These are Monday’s market winners and losers.

Biggest Winners

Shares of IRIS International Inc. (NASDAQ: IRIS) are up 44.93% to $19.45 on trading volume of 1.4 million shares. Danaher Corp. (NYSE: DHR) said it would buy the medical firm for $355 million, or $19.50 a share. Before Monday, the 52-week high was $13.92.

Shares of Complete Genomics Inc. (NASDAQ: GNOM) are up 14.61% to $3.06 on trading volume of 3.9 million shares. Chinese firm BGI-Shenzhen is buying the company for $117.6 million, or $3.15 a share. The 52-week high is $7.73.

Biggest Losers

Shares of Threshold Pharmaceuticals Inc. (NASDAQ: THLD) are down 26.84% to $6.38 on trading volume of 6 million shares. The company reported mixed results following a clinical trial for its drug which treats pancreatic cancer. The 52-week low is $1.18.

Shares of Groupon Inc. (NASDAQ: GRPN) are down 6.07% to $4.95 on trading volume of 3.3 million shares. Investment bank Evercore Partners has added the daily deals company to its “Conviction Sell List,” according to flyonthewall.com. The 52-week low is $4.00.

Samuel Weigley

Follow him on Twitter: SWeigley

Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)

Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.

Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.

Click here now to get started.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.